These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 25150259)

  • 1. High expression of transcription factor 4 (TCF4) is an independent adverse prognostic factor in acute myeloid leukemia that could guide treatment decisions.
    in 't Hout FE; van der Reijden BA; Monteferrario D; Jansen JH; Huls G
    Haematologica; 2014 Dec; 99(12):e257-9. PubMed ID: 25150259
    [No Abstract]   [Full Text] [Related]  

  • 2. Unique genome-wide map of TCF4 and STAT3 targets using ChIP-seq reveals their association with new molecular subtypes of glioblastoma.
    Zhang JX; Zhang J; Yan W; Wang YY; Han L; Yue X; Liu N; You YP; Jiang T; Pu PY; Kang CS
    Neuro Oncol; 2013 Mar; 15(3):279-89. PubMed ID: 23295773
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nuclear LEF1/TCF4 correlate with poor prognosis but not with nuclear β-catenin in cerebral metastasis of lung adenocarcinomas.
    Bleckmann A; Siam L; Klemm F; Rietkötter E; Wegner C; Kramer F; Beissbarth T; Binder C; Stadelmann C; Pukrop T
    Clin Exp Metastasis; 2013 Apr; 30(4):471-82. PubMed ID: 23224985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression profiling of cancer-related galectins in acute myeloid leukemia.
    El Leithy AA; Helwa R; Assem MM; Hassan NH
    Tumour Biol; 2015 Sep; 36(10):7929-39. PubMed ID: 25953264
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Downregulation of the Wnt inhibitor CXXC5 predicts a better prognosis in acute myeloid leukemia.
    Kühnl A; Valk PJ; Sanders MA; Ivey A; Hills RK; Mills KI; Gale RE; Kaiser MF; Dillon R; Joannides M; Gilkes A; Haferlach T; Schnittger S; Duprez E; Linch DC; Delwel R; Löwenberg B; Baldus CD; Solomon E; Burnett AK; Grimwade D
    Blood; 2015 May; 125(19):2985-94. PubMed ID: 25805812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MN1, FOXP1 and hsa-miR-181a-5p as prognostic markers in acute myeloid leukemia patients treated with intensive induction chemotherapy and autologous stem cell transplantation.
    Seipel K; Messerli C; Wiedemann G; Bacher U; Pabst T
    Leuk Res; 2020 Feb; 89():106296. PubMed ID: 31927137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The outcomes of relapsed acute myeloid leukemia in children: Results from the Japanese Pediatric Leukemia/Lymphoma Study Group AML-05R study.
    Moritake H; Tanaka S; Miyamura T; Nakayama H; Shiba N; Shimada A; Terui K; Yuza Y; Koh K; Goto H; Kakuda H; Saito A; Hasegawa D; Iwamoto S; Taga T; Adachi S; Tomizawa D
    Pediatr Blood Cancer; 2021 Jan; 68(1):e28736. PubMed ID: 32991072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Up-regulation of DDIT4 predicts poor prognosis in acute myeloid leukaemia.
    Cheng Z; Dai Y; Pang Y; Jiao Y; Liu Y; Cui L; Quan L; Qian T; Zeng T; Si C; Huang W; Chen J; Pang Y; Ye X; Shi J; Fu L
    J Cell Mol Med; 2020 Jan; 24(1):1067-1075. PubMed ID: 31755224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. WT1 Expression in Adult Acute Myeloid Leukemia: Assessing its Presence, Magnitude and Temporal Changes as Prognostic Factors.
    Ujj Z; Buglyó G; Udvardy M; Beyer D; Vargha G; Biró S; Rejtő L
    Pathol Oncol Res; 2016 Jan; 22(1):217-21. PubMed ID: 26531831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes of Intermediate Risk Karyotype Acute Myeloid Leukemia in First Remission Undergoing Autologous Stem Cell Transplantation Compared With Allogeneic Stem Cell Transplantation and Chemotherapy Consolidation: A Retrospective, Propensity-score Adjusted Analysis.
    Limvorapitak W; Barnett MJ; Hogge DE; Forrest DL; Nevill TJ; Narayanan S; Power MM; Nantel SH; Broady R; Song KW; Toze CL; Mourad YA; Sutherland HJ; Gerrie AS; White J; Sanford DS
    Clin Lymphoma Myeloma Leuk; 2018 Nov; 18(11):e481-e491. PubMed ID: 30100330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression profile and specific network features of the apoptotic machinery explain relapse of acute myeloid leukemia after chemotherapy.
    Ragusa M; Avola G; Angelica R; Barbagallo D; Guglielmino MR; Duro LR; Majorana A; Statello L; Salito L; Consoli C; Camuglia MG; Di Pietro C; Milone G; Purrello M
    BMC Cancer; 2010 Jul; 10():377. PubMed ID: 20642818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of mitochondrial genes predicts survival in pediatric acute myeloid leukemia.
    Tyagi A; Pramanik R; Bakhshi R; Singh A; Vishnubhatla S; Bakhshi S
    Int J Hematol; 2019 Aug; 110(2):205-212. PubMed ID: 31119613
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A 4-gene expression prognostic signature might guide post-remission therapy in patients with intermediate-risk cytogenetic acute myeloid leukemia.
    Torrebadell M; Díaz-Beyá M; Kalko SG; Pratcorona M; Nomdedeu J; Navarro A; Gel B; Brunet S; Sierra J; Camós M; Esteve J
    Leuk Lymphoma; 2018 Oct; 59(10):2394-2404. PubMed ID: 29390924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of genetic profiling on prediction of therapeutic resistance and survival in adult acute myeloid leukemia.
    Walter RB; Othus M; Paietta EM; Racevskis J; Fernandez HF; Lee JW; Sun Z; Tallman MS; Patel J; Gönen M; Abdel-Wahab O; Levine RL; Estey EH
    Leukemia; 2015 Oct; 29(10):2104-7. PubMed ID: 25772026
    [No Abstract]   [Full Text] [Related]  

  • 15. Hypoxia inducible factor (HIF)-2α accelerates disease progression in mouse models of leukemia and lymphoma but is not a poor prognosis factor in human AML.
    Forristal CE; Brown AL; Helwani FM; Winkler IG; Nowlan B; Barbier V; Powell RJ; Engler GA; Diakiw SM; Zannettino AC; Martin S; Pattabiraman D; D'Andrea RJ; Lewis ID; Levesque JP
    Leukemia; 2015 Oct; 29(10):2075-85. PubMed ID: 25921247
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.
    Schwind S; Marcucci G; Maharry K; Radmacher MD; Mrózek K; Holland KB; Margeson D; Becker H; Whitman SP; Wu YZ; Metzeler KH; Powell BL; Kolitz JE; Carter TH; Moore JO; Baer MR; Carroll AJ; Caligiuri MA; Larson RA; Bloomfield CD
    Blood; 2010 Dec; 116(25):5660-9. PubMed ID: 20841507
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene expression profiling of acute myeloid leukemia samples from adult patients with AML-M1 and -M2 through boutique microarrays, real-time PCR and droplet digital PCR.
    Handschuh L; Kaźmierczak M; Milewski MC; Góralski M; Łuczak M; Wojtaszewska M; Uszczyńska-Ratajczak B; Lewandowski K; Komarnicki M; Figlerowicz M
    Int J Oncol; 2018 Mar; 52(3):656-678. PubMed ID: 29286103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simple acute phase protein score to predict long-term survival in patients with acute myeloid leukemia.
    Heini AD; Hugo R; Berger MD; Novak U; Bacher U; Pabst T
    Hematol Oncol; 2020 Feb; 38(1):74-81. PubMed ID: 31755141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The expression of Toll-like receptors in patients with acute myeloid leukemia treated with induction chemotherapy.
    Rybka J; Butrym A; Wróbel T; Jaźwiec B; Stefanko E; Dobrzyńska O; Poręba R; Kuliczkowski K
    Leuk Res; 2015 Mar; 39(3):318-22. PubMed ID: 25624047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. INPP4B overexpression is associated with poor clinical outcome and therapy resistance in acute myeloid leukemia.
    Dzneladze I; He R; Woolley JF; Son MH; Sharobim MH; Greenberg SA; Gabra M; Langlois C; Rashid A; Hakem A; Ibrahimova N; Arruda A; Löwenberg B; Valk PJ; Minden MD; Salmena L
    Leukemia; 2015 Jul; 29(7):1485-95. PubMed ID: 25736236
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.